Shephard Mpofu

5.4k total citations · 3 hit papers
68 papers, 4.1k citations indexed

About

Shephard Mpofu is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Shephard Mpofu has authored 68 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Rheumatology, 42 papers in Hematology and 41 papers in Immunology. Recurrent topics in Shephard Mpofu's work include Spondyloarthritis Studies and Treatments (46 papers), Autoimmune and Inflammatory Disorders Research (42 papers) and Psoriasis: Treatment and Pathogenesis (39 papers). Shephard Mpofu is often cited by papers focused on Spondyloarthritis Studies and Treatments (46 papers), Autoimmune and Inflammatory Disorders Research (42 papers) and Psoriasis: Treatment and Pathogenesis (39 papers). Shephard Mpofu collaborates with scholars based in United States, Switzerland and United Kingdom. Shephard Mpofu's co-authors include Hanno B. Richards, Philip J. Mease, Luminita Pricop, Iain B. McInnes, Proton Rahman, Désirée van der Heijde, Bruce Kirkham, Ruvie Martin, R. Landewé and Xenofon Baraliakos and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of the Rheumatic Diseases.

In The Last Decade

Shephard Mpofu

68 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

2015 732 citations Mats Andersson, Shephard Mpofu et al. profile →
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 650 citations Iain B. McInnes, Philip J. Mease et al. profile →
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

2015 572 citations Philip J. Mease, Iain B. McInnes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shephard Mpofu United States	24	2.9k	2.9k	1.8k	520	252	68	4.1k
Luminita Pricop United States	30	3.5k 1.2×	2.7k 0.9×	1.6k 0.9×	531 1.0×	531 2.1×	115	4.7k
Daniel Burge United States	14	1.6k 0.6×	2.6k 0.9×	1.5k 0.8×	355 0.7×	305 1.2×	23	3.9k
Elizabeth C. Hsia United States	34	1.7k 0.6×	3.1k 1.1×	1.6k 0.9×	254 0.5×	135 0.5×	109	3.9k
Rubén Queiró Spain	30	1.9k 0.6×	1.9k 0.6×	877 0.5×	425 0.8×	243 1.0×	192	2.9k
Hanno B. Richards United States	35	3.5k 1.2×	3.4k 1.2×	1.5k 0.8×	411 0.8×	544 2.2×	58	5.0k
Mittie K. Doyle United States	24	1.4k 0.5×	2.0k 0.7×	1.2k 0.6×	367 0.7×	139 0.6×	41	3.1k
Barbara Finck United States	8	1.3k 0.5×	2.7k 0.9×	1.5k 0.9×	184 0.4×	268 1.1×	17	3.6k
Aileen L. Pangan United States	35	2.0k 0.7×	4.0k 1.4×	2.0k 1.1×	722 1.4×	221 0.9×	94	5.4k
Lianne S. Gensler United States	27	1.7k 0.6×	2.5k 0.9×	950 0.5×	111 0.2×	230 0.9×	165	3.0k
Joseph Wajdula United States	21	1.1k 0.4×	2.7k 0.9×	1.2k 0.7×	174 0.3×	161 0.6×	35	3.4k

Countries citing papers authored by Shephard Mpofu

Since Specialization

Citations

This map shows the geographic impact of Shephard Mpofu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shephard Mpofu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shephard Mpofu more than expected).

Fields of papers citing papers by Shephard Mpofu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shephard Mpofu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shephard Mpofu. The network helps show where Shephard Mpofu may publish in the future.

Co-authorship network of co-authors of Shephard Mpofu

This figure shows the co-authorship network connecting the top 25 collaborators of Shephard Mpofu. A scholar is included among the top collaborators of Shephard Mpofu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shephard Mpofu. Shephard Mpofu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taylor, Peter C., Philip J. Mease, Kurt de Vlam, et al.. (2025). Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Annals of the Rheumatic Diseases. 84(6). 979–991. 2 indexed citations

Ugradar, Shoaib, et al.. (2024). 12318 Preliminary Safety and Efficacy of Subcutaneous Lonigutamab (anti-IGF-1R) from a Phase 1/2 Proof of Concept Study in Patients with Thyroid Eye Disease. Journal of the Endocrine Society. 8(Supplement_1). 2 indexed citations

Behrens, Frank, et al.. (2024). LBA0005 EFFICACY AND SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 16 RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2b/3 STUDY. Annals of the Rheumatic Diseases. 83. 235–236. 2 indexed citations

Mease, Philip J., Robert Landewé, Proton Rahman, et al.. (2021). Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 7(2). e001600–e001600. 26 indexed citations

Heijde, Désirée van der, Philip J. Mease, Robert Landewé, et al.. (2019). Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Lara D. Veeken. 59(6). 1325–1334. 45 indexed citations

Coates, Laura C., Philip J. Mease, Laure Gossec, et al.. (2018). Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2‐Year Results From a Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase III Study. Arthritis Care & Research. 70(10). 1529–1535. 37 indexed citations

Nash, Peter, Philip J. Mease, Iain B. McInnes, et al.. (2018). Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Research & Therapy. 20(1). 47–47. 128 indexed citations

Thom, Howard, Iain B. McInnes, Peter Nash, et al.. (2016). Psoriatic Arthritis Response Criteria Scores: Results From A Placebo-Response Adjusted Network Meta-Analysis With Secukinumab. Value in Health. 19(3). A226–A226. 3 indexed citations

Nash, Peter, Philip Mease, Iain B. McInnes, et al.. (2016). Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results From a Pooled Safety Analysis. Internal Medicine Journal. 46. 39–39. 2 indexed citations

10.

Heijde, Désirée van der, Robert Landewé, Philip J. Mease, et al.. (2016). Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis & Rheumatology. 68(8). 1914–1921. 61 indexed citations

11.

McInnes, Iain B., B. W. Kirkham, Arthur Kavanaugh, et al.. (2015). Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Journal of Investigative Dermatology. 135. 2 indexed citations

12.

Mease, Philip J., Iain B. McInnes, Bruce Kirkham, et al.. (2015). Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 67. 2576–2578. 4 indexed citations

13.

Mease, Philip, Iain B. McInnes, Bruce Kirkham, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 66. 12 indexed citations

14.

McInnes, Iain B., Philip J. Mease, Bruce Kirkham, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing. Data Archiving and Networked Services (DANS). 66(12). 3529–3529. 19 indexed citations

15.

Landewé, Robert, Iain B. McInnes, Philip G. Conaghan, et al.. (2014). Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 66. 42–43. 16 indexed citations

16.

Gottlieb, Alice B., Philip Mease, Iain B. McInnes, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 66. 12 indexed citations

17.

Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2014). One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. The Journal of Rheumatology. 41(3). 414–421. 83 indexed citations

18.

Strand, Vibeke, Mark Kosinski, Ari Gnanasakthy, Usha G. Mallya, & Shephard Mpofu. (2014). Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health and Quality of Life Outcomes. 12(1). 31–31. 19 indexed citations

19.

Kosinski, Mark, Jakob Bue Bjørner, Ari Gnanasakthy, Usha G. Mallya, & Shephard Mpofu. (2013). Applying Item Response Theory Methods to Improve the Measurement of Fatigue in a Clinical Trial of Rheumatoid Arthritis Patients Treated with Secukinumab*. 3(4). 192–201. 1 indexed citations

20.

Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2012). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals of the Rheumatic Diseases. 72(6). 863–869. 227 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact